All Oncology News

An FDA panel voted against approval of the immunotherapy MCNA as a treatment for patients with high-risk non-muscle invasive bladder cancer following first-line bacillus Calmette-Guérin therapy.

The FDA has granted a breakthrough therapy designation to avelumab as a potential treatment for patients with metastatic Merkel cell carcinoma following progression on at least one prior chemotherapy regimen.

Oligometastatic prostate cancer is optimally treated with the combination of docetaxel and androgen deprivation therapy.

Dr. Thomas Kipps discusses how challenges in CLL may be met in the future and the impact obinutuzumab, venetoclax, and other novel agents could have on CLL treatment.

The FDA has assigned a priority review designation to the PD-1 inhibitor nivolumab as a treatment for patients with advanced renal cell carcinoma following prior antiangiogenic therapy.

A phase III study exploring idelalisib in combination with bendamustine and rituximab for patients with previously treated chronic lymphocytic leukemia has been stopped early following a positive interim analysis.

The FDA has granted an accelerated approval to the CD38-targeted monoclonal antibody daratumumab as a monotherapy for patients with multiple myeloma following at least 3 prior therapies.

The dramatic and often practice-changing findings demonstrated by trials of immunotherapies in melanoma and lung cancer may soon be reflected in the treatment of bladder cancer.

The FDA has requested additional clinical trial data to support a new drug application for rociletinib as a potential therapy for pretreated patients with EGFR T790M mutation-positive NSCLC.

A supplemental new drug application has been submitted for ibrutinib (Imbruvica) for use in combination with bendamustine and rituximab to treat patients with relapsed or refractory chronic lymphocytic leukemia.

Researchers are starting to understand which patients with castration-resistant prostate cancer (CRPC) may benefit most from treatment with radium-223.

The FDA has granted an accelerated approval to osimertinib for patients with advanced EGFR T790M mutation positive non–small cell lung cancer following prior therapy on a prior EGFR TKI.

Michael Morris, MD, discusses the potential of radium-223 and how the agent could be successful and impactful in metastatic castration-resistant prostate cancer.

International study co-led by Dr. Antoni Ribas finds vemurafenib and cobimetinib extend lives and decrease risk of side effects in men and women with melanoma.

CEO and physician James Bianco, a Bronx native and Mount Sinai alumnus, establishes endowment to address area of cancer with unmet need to bring more effective therapies to patients.

Strategic Alliance Partnership will strengthen outreach to cancer patients.

Robert Figlin, MD, and Daniel Petrylak, MD, discuss emerging agents in RCC they are excited about and what challenges still remain in treating the disease.

Shaji Kumar, MD, discusses how newly approved agents and other changes have affected the treatment of multiple myeloma and what is on the horizon for the disease.

Ponatinib is effective against the T315I mutation, which is a leading cuase of resistance, and has shown sustainable responses in patients with Ph+ acute lymphoblastic leukemia.

The FDA has approved the combination of vemurafenib and cobimetinib as a treatment for patients with metastatic or unresectable BRAF V600E/K mutation-positive melanoma.

The American Society of Hematology said it is deeply unsatisfied with the findings of a task force that convened to review Maintenance of Certification standards for the American Board of Internal Medicine.

Combinations of targeted therapies continue to advance toward full regulatory approval for patients with metastatic or unresected melanoma, given the substantial benefits seen with these agents.

The combination of lenalidomide and rituximab demonstrated an objective response rate of 92% as initial therapy for patients with mantle cell lymphoma.

Immune checkpoint blockade has transformed the treatment paradigms of multiple advanced solid tumors-and bladder cancer is no exception.

OncLive is proud to announce that nominations are open for the 4th Annual Giants of Cancer Care awards. The Giants of Cancer Care program celebrates the achievements of leading physicians and researchers who have devoted their time, talent and resources to improving care for the many patients and their families affected by cancer.

Mutations in MYD88 and CXCR4 can effectively be used to tailor treatment for patients with Waldenström's macroglobulinemia.

The FDA has granted a breakthrough therapy designation to pexidartinib as a potential therapy for patients with tenosynovial giant cell tumor for which surgical removal is contraindicate.

The PARP inhibitor olaparib had an overall response rate of nearly 90% in a biomarker-defined subgroup of patients with metastatic castration-resistant prostate cancer who had DNA-repair defects.

The FDA has granted a breakthrough therapy designation to pembrolizumab as a potential therapy for patients with microsatellite instability-high metastatic colorectal cancer.

Robert J. Motzer, MD, discusses nivolumab's impact for renal cell carcinoma treatment.